iForum™ 2021 Virtual User Group


The Premier Virtual Differentiated iPSC Meeting - From Ideation to Implementation

The first virtual iForum™ meeting where innovators from academia, government, biotech, and pharma will detail breakthrough applications enabled by differentiated human iPSCs.

Dates

This meeting was held online, Wednesday, January 27th and Thursday, January 28th, 2021.

View the iForum Session Videos

Please complete the form below to access the iForum sessions:

Speakers

  • Caroline Archer, PhD - AstraZeneca
  • Silvia Cainarca, PhD - AXXAM, S.p.A.
  • Coby Carlson, PhD - Director of Innovation & New Technologies, FUJIFILM Cellular Dynamics
  • Elena Dragicevic, PhD, Senior Sales and Alliance Manager - Nanion Technologies
  • Todd Herron, PhD, Associate Research Scientist and Director of the UM Cardiovascular Regeneration Core Laboratory - University of Michigan
  • Yasunari Kanda, PhD - National Institute of Health Sciences, Japan
  • Tomohiro Kawamoto, PhD - Axcelead Drug Discovery Partners
  • Camille Nicoleau, PhD - IPSEN
  • Francesca Pistollato, PhD - European Commission, Joint Research Centre
  • Szilard Sajgo, PhD - R&D Scientist, Maxwell Biosystems
  • Frederick Sannajust, PhD - Independent Safety Pharmacology/Toxicology Consultant, Former Executive Director of Safety and Exploratory Safety Pharmacology at MERCK Research Laboratories, West-Point, PA, USA.
  • Ilyas Singeç, MD, PhD - Director of the Stem Cell Translation Laboratory; Division of Preclinical Innovation National Center for Advancing Translational Sciences (NCATS)
  • Takahiro Tanaka, PhD, RPh - Axcelead Drug Discovery Partners
  • Marija Usenovic, PhD - Merck & Co
  • Alison Walker, PhD - AstraZeneca

Research-focused Agenda

iForum 2021 Meeting agenda is packed with thought-provoking and visionary scientific presentations. This 2 half-day event featured the use of human iPSC-derived cells for disease modeling, drug discovery and predictive toxicology in the cardiac and neural fields.

Day 1

iPSC-derived Cardiomyocytes in Discovery and Safety Pharmacology


Time

Session

Speakers


9:00 am CST
(4:00pm CET)
Welcome - Opening Remarks

9:15 am Cardiac Microtissues: High Throughput Profiling for Structural Cardiotoxicity Caroline Archer, PhD
Associate Principal Scientist
and
Alison Walker, PhD
Senior Research Scientist
AstraZeneca

9:45 am Thinking Outside the Cardiac Box: Ion Channel Physiology in iPSC-CMs in a Virtual or Mechanically Induced Pro-maturation Environment Elena Dragicevic, PhD
Senior Sales and Alliance Manager
Nanion Technologies

10:15 am Converging Technologies to Enhance the Functionality and Predictivity of hiPSC-Derived Cardiomyocytes Coby Carlson, PhD
Director of Innovation & New Technologies
FUJIFILM Cellular Dynamics

10:45 am Evaluation of the Efficacy and Safety of Anti-COVID-19 Drugs Using iPSC Cardiomyocytes Yasunari Kanda, PhD
Division Head
National Institute of Health Sciences, Japan

11:15am Panel Discussion: Trends in Safety Pharmacology and Toxicology Frederick Sannajust, PhD
Independent Safety Pharmacology/Toxicology Consultant, Former Executive Director of Safety and Exploratory Safety Pharmacology
Merck Research Laboratories, USAYasunari Kanda, PhD
Division Head
National Institute of Health Sciences JapanTodd Herron, PhD
Associate Research Scientist and Director of the UM Cardiovascular Regeneration Core Laboratory
University of MichiganAdditional panelists to be announced

12:15 pm CST
(7:15pm CET)
Closing Remarks - Day 1

 

Day 2

iPSC-derived Neurons in Discovery and Tox Testing


Time

Session

Speakers


9:00 am CST
(4:00 pm CET)
Welcome

9:10 am Driving Innovative Drug Discovery Using Target-Oriented Hit Identification Assays and Phenotypic Screening Takahiro Tanaka, PhD, RPh
Director
and
Tomohiro Kawamoto
Director
Axcelead Drug Discovery Partners

9:30 am hiPSC-Derived Neurons Provide a Robust and Physiologically Relevant In Vitro Platform to Test Botulinum Neurotoxins Camille Nicoleau, PhD
Team Lead - in vitro Efficacy/Cellular Mechanism
IPSEN (France)

10:00 am The Use of Human iPS-Derived Neuronal Model for Developmental Neurorotoxicity Testing and Mixture Risks Assessment Francesca Pistollato, PhD
Scientific Officer - European Commission
Joint Research Centre (Ispra), Italy

10:30 am Riding the Calcium Wave on iCell® GlutaNeurons During HTS Silvia Cainarca, PhD
iPSC Unit Manager, PI
AXXAM, S.p.A

11:00 am Leveraging iPS Cell Translation Ilyas Singeç, MD, PhD
Director of the Stem Cell Translation Laboratory; Division of Preclinical Innovation
National Center for Advancing Translational Sciences (NCATS), NIH

11:30 am Modeling of Neurodegenerative Phenotypes in Human iPSC Neurons Marija Usenovic, PhD
Associate Principal Scientist
Merck & Co, USA

12:00 pm High-Content Electrophysiology for Phenotype Characterization of Human iPSC-Derived Neuronal Cell Lines Szilard Sajgo, PhD
R&D Scientist
Maxwell Biosytems

12:30 pm CST
(7:30 pm CET)
Closing Statements - Day 2

Partners

AXXAM Nanion

Event Details:

Event Date: 2021-01-27 To 2021-01-28

Organiser: FUJIFILM Cellular Dynamics

Website: